Alerts will be sent to your verified email
Verify EmailCONCORDBIO
Balance sheet of Concord Biotech is strong.
It shouldn't have solvency or liquidity issues.
Yes, The debt of Concord Biotech is increasing.
Latest debt of Concord Biotech is -₹8.46 Crs as of Sep-24.
This is greater than Mar-24 when it was -₹87.79 Crs.
Yes, profit is increasing.
The profit of Concord Biotech is ₹328 Crs for TTM, ₹308 Crs for Mar 2024 and ₹240 Crs for Mar 2023.
The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Concord Biotech latest dividend payout ratio is 29.71% and 3yr average dividend payout ratio is 29.1%
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Accounts Receivable